AIMMUNE THERAPEUTICS, INC.
CIK 0001631650
Revenue (TTM)
—
Q2 Jul 2020
Net Income (TTM)
−$283.01M
−3.8% YoY
Q2 Jul 2020
EPS Diluted (TTM)
—
Q2 Jul 2020
Gross Margin
—
Q2 Jul 2020
Operating Margin
—
Q2 Jul 2020
Net Margin
—
Q2 Jul 2020
Free Cash Flow (TTM)
−$341.52M
Q2 Jul 2020
Cash
$266.56M
Q2 Jul 2020
Total Debt
$131.46M
Q2 Jul 2020
Shares Outstanding
65.45M sh
Q2 Jul 2020
Revenue & Net Income
Cash Flow
Revenue Growth (YoY)
No data available for this metric.